Results 41 to 50 of about 60,435,326 (243)
, 2003 Interleukin-18 (IL-18), a recently described member of the IL-1 cytokine superfamily, is now recognized as an important regulator of innate and acquired immune responses.
McInnes, I.B. +2 more
core +1 more source
The interleukin‐23 axis in intestinal inflammation
Immunological Reviews, 2008 Summary: Immune responses in the intestine are tightly regulated to ensure host protective immunity in the absence of immune pathology. Interleukin‐23 (IL‐23) has recently been shown to be a key player in influencing the balance between tolerance and immunity in the intestine.
Ahern, P, Izcue, A, Maloy, K, Powrie, F
openaire +2 more sources
FEBS Letters, EarlyView.Enteropathogenic E. coli (EPEC) infects the human intestinal epithelium, resulting in severe illness and diarrhoea. In this study, we compared the infection of cancer‐derived cell lines with human organoid‐derived models of the small intestine. We observed a delayed in attachment, inflammation and cell death on primary cells, indicating that host ...
Mastura Neyazi +5 more
wiley +1 more source
ES-62 protects against collagen-induced arthritis by resetting interleukin-22 towards resolution of inflammation in the joints [PDF]
, 2014 Objective. The parasitic worm–derived immunomodulator ES-62 protects against disease in the mouse collagen-induced arthritis (CIA) model of rheumatoid arthritis (RA) by suppressing pathogenic interleukin-17 (IL-17) responses. The Th17 associated cytokine
Al-Riyami, Lamyaa +12 more
core +2 more sources
Российский журнал гастроэнтерологии, гепатологии, колопроктологииAim. To compare the efficacy and safety of interleukin (IL)-23 and IL-12/23 inhibitors during the induction and maintenance phases of Crohn’s disease using a Bayesian network meta-analysis.Materials and methods.
S. Alvianto +3 more
doaj +1 more source
Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential
FEBS Letters, EarlyView.Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta +3 more
wiley +1 more source
IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?
Frontiers in Immunology, 2021 Axial spondyloarthritis is a prevalent form of chronic arthritis which is related to psoriatic arthritis and skin psoriasis. TNF and IL-17A as well as IL-17F are key cytokines contributing to the pathobiology of this disease, as evidence by the ...
Dominique Baeten +2 more
doaj +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Interleukin-23: A central cytokine in the pathogenesis of spondylarthritis [PDF]
Arthritis & Rheumatism, 2011 One of the most satisfying aspects of the genome-wide association studies conducted in patients withankylosing spondylitis (AS) has been the large numberof genes that have been shown to affect susceptibility todisease (1). The first gene of this kind to be identifiedwas the interleukin-23 receptor (IL-23R).
Gaston, J. S. Hill +2 more
openaire +2 more sources
, 2015 Objective To investigate the distribution of interleukin (IL)-12 (IL12; 1188A/C), IL17 (A7488G) and IL-23 receptor (IL23R; +2199A/C) gene polymorphisms in patients with alopecia ...
Pehlivan, Sacide +4 more
core +1 more source